SCHEMBL10112951

SCHEMBL10112951

CCOC(=O)C1=C(C)NC(=O)NC1c1ccc(O)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.76
KIF11 P52732 1/20 0.73
CA12 O43570 1/20 0.72
CA1 P00915 1/20 0.72
CA2 P00918 1/20 0.72
CA7 P43166 1/20 0.72
CA9 Q16790 1/20 0.72
L3MBTL1 Q9Y468 1/20 0.69
ADORA2B P29275 3/20 0.67
MAPK1 P28482 3/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
ALDH1A1 P00352 3/20 0.67
GAA P10253 1/20 0.67
ALOX15 P16050 1/20 0.66
MAPK10 P53779 1/20 0.66
KDM4E B2RXH2 1/20 0.64
TSHR P16473 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1227524 0.90 HSD17B10 (0.77) HSD17B10KIF11CA12CA1CA2
SCHEMBL19752680 0.90 HSD17B10 (0.77) HSD17B10KIF11CA12CA1CA2
SCHEMBL5340705 0.89 HSD17B10 (0.75) HSD17B10KIF11CA12CA1CA2
SCHEMBL28490632 0.88 HSD17B10 (0.73) HSD17B10KIF11CA12CA1CA2
SCHEMBL19752622 0.88 MAPT (0.78) HSD17B10KIF11CA12CA1CA2
SCHEMBL5340383 0.88 MAPT (0.78) HSD17B10KIF11CA12CA1CA2
SCHEMBL19752649 0.88 MAPT (0.78) HSD17B10KIF11CA12CA1CA2
SCHEMBL18025267 0.88 KIF11 (0.75) HSD17B10KIF11CA12CA1CA2
SCHEMBL5347891 0.88 KIF11 (0.75) HSD17B10KIF11CA12CA1CA2
SCHEMBL19752667 0.88 KIF11 (0.75) HSD17B10KIF11CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110437100-B Preparation method and application of novel ionic salicylaldehyde Schiff base zirconium complex 山西医科大学 2022-03-11 CN disclosed
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-9815838-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2017-11-14 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN HYDRA BIOSCIENCES, INC. (US) 2014-08-07 US disclosed
US-8389529-B2 Methods and compositions for treating asthma HYDRA BIOSCIENCES, INC. (US) 2013-03-05 US disclosed
US-8389529-B2 Methods and compositions for treating asthma HYDRA BIOSCIENCES, INC. (US) 2013-03-05 US disclosed
US-8178542-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2012-05-15 US disclosed
US-8178542-B2 Methods and compositions for treating pain HYDRA BIOSCIENCES, INC. (US) 2012-05-15 US disclosed
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ELI LILLY AND COMPANY 2010-10-21 US disclosed
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ELI LILLY AND COMPANY 2010-10-21 US disclosed
US-7671061-B2 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES, INC. (US) 2010-03-02 US disclosed
US-7671061-B2 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES, INC. (US) 2010-03-02 US disclosed
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES (US) 2007-09-20 US disclosed
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence HYDRA BIOSCIENCES (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267750-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ACHE, COL2A1, MMP8 HSD17B10 808/4885KIF11 1427/4885CA12 115/4885
US-20070219222-A1 Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence TRPA1, TRPV1, TRPV2 HSD17B10 2793/4885KIF11 3117/4885CA12 3289/4885
US-20140221401-A1 METHODS AND COMPOSITIONS FOR TREATING PAIN ACHE, COL2A1, MMP8 HSD17B10 808/4885KIF11 1427/4885CA12 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.